Showing results (201-210 of 209) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapiesVincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyMichael A Postow, Peter D Zang, Sumanta K Pal, et al.
Cancer Discovery|November 23, 2018
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 12, 2023
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patientsAudrey Mauguen, Ravinder K Grewal, Finn Augensen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2025
Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial ChemotherapyAlexander Ramos, Andrew L A Garton, Jared Knopman, et al.
Clinical and Translational Imaging|February 12, 2025
Epichaperome-targeted myocardial imaging by 124I-PU-H71 PETSonia Mahajan, Milan Grkovski, Kevin D Staton, et al.
The Lancet. Diabetes & Endocrinology|April 3, 2023
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variantsDavid Taïeb, George B Wanna, Maleeha Ahmad, et al.
Transfusion|April 20, 2019
Reexamination of the chromium-51-labeled posttransfusion red blood cell recovery methodRichard O Francis, Sonia Mahajan, Francesca Rapido, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Pageof 21